1.Effect of long term glucocorticoid treatment on human growth hormone secretion in children and adolescents and the safety and effectiveness of recombinant human growth hormone treatment.
Li KANG ; Zhang DIAN-CHI ; Wu QI-YONG ; Zhu HUI-JUAN ; Gong FENG-YANG ; Pan HUI ; Jin ZI-MENG ; Deng JIE-YING ; Shi YI-FAN
Acta Academiae Medicinae Sinicae 2011;33(1):1-4
OBJECTIVELong term glucocorticoid (prednisolone) treatment on human growth hormone (hGH) secretion in children and adolescents and to investigate the effectiveness and safety of the recombinant human growth hormone (rhGH) treatment.
METHODSTwelve patients (age: 10.4∓1.2 years) who were treated in Peking Union Medical College Hospital from September 1999 to November 2009 were enrolled in this study. All of them had taken prednisolone with a dose of 0.5∓2.0 mg/(kg.d) for 6~18 months. Two different hGH stimulating tests was done and their growth and development was evaluated at regular intervals. Seven patients were given rhGH with a dose of 0.1 U/(kg.d) for 6~12 months to improve their growth and development after half a year of prednisolone withdrawal when their disease conditions were improved.
RESULTSThe growth speed of these 12 children decreased significantly during prednisolone treatment compared with before prednisolone treatment (1.2∓0.3cm/year vs.3.7∓1.2 cm/year,P12 months than those with a 6~12 months course (P0.05). The growth speed of seven children who received rhGH therapy for half a year were increased from 2.2∓0.1cm/year to 7.8∓0.5cm/year (P<0.05), and then to 6.9∓0.4cm/year one year later.
CONCLUSIONSThe long-term glucocorticoid treatment can decrease the hGH secretion, and thus leads to short stature and agenesis. However, the rhGH replacement can safely and effectively improve growth and development in these children after their primary diseases are improved and glucocorticoids are withdrawn.
Adolescent ; Child ; Female ; Follow-Up Studies ; Glucocorticoids ; adverse effects ; therapeutic use ; Human Growth Hormone ; secretion ; therapeutic use ; Humans ; Male ; Recombinant Proteins ; therapeutic use ; Treatment Outcome
2.Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery.
Jian YIN ; Chang-bao SU ; Zhi-qin XU ; Yi YANG ; Wen-bin MA ; Wei TAO ; Zhong YANG ; Xue-wei XIA
Chinese Medical Sciences Journal 2005;20(1):23-26
OBJECTIVETo investigate whether somatostatin analog octreotide long acting release (LAR) shrinks growth hormone (GH) secreting adenomas, and improves the results of subsequent transsphenoidal surgery.
METHODSSeventeen previously untreated active acromegalic patients with pituitary adenomas were treated with LAR (30 mg intramuscular injection every 28 days) for 3 months prior to transsphenoidal surgery. Clinical reaction, mean GH secretion, and tumor volume were measured under basal conditions and after LAR treatment.
RESULTSPresurgical treatment improved acromegaly symptoms and induced a significant reduction of GH under the 5 ng/mL limit in microadenoma (P < 0.05), while only 18.2% (2/11) in macroadenoma. Meanwhile, tumor shrinkage occurred in 58.8% (10/17) patients, with 1 case in the microadenoma group. All marked shrinkage (> 25%) occurred in the macroadenoma group. Statistical analysis showed tumor shrinkage caused by LAR was greater in macroadenoma group than that in microadenoma group (P < 0.05). During operation, adenoma was soft in 15 cases, with the exception of 2 cases in which the soft tumor was divided by fibrous septa, but all tumor removal was smooth.
CONCLUSIONSA short term administration of preoperative LAR may induce a significant decrease in GH-secretion level and adenoma volume. Presurgical use of octreotide LAR improves surgical results especially in macroadenomas.
Acromegaly ; drug therapy ; Adenoma ; drug therapy ; secretion ; surgery ; Adult ; Antineoplastic Agents, Hormonal ; administration & dosage ; therapeutic use ; Delayed-Action Preparations ; Female ; Human Growth Hormone ; secretion ; Humans ; Hypophysectomy ; methods ; Male ; Middle Aged ; Octreotide ; administration & dosage ; therapeutic use ; Pituitary Neoplasms ; drug therapy ; secretion ; surgery ; Preoperative Care
3.The Ability of beta-Cells to Compensate for Insulin Resistance is Restored with a Reduction in Excess Growth Hormone in Korean Acromegalic Patients.
Soo Kyoung KIM ; Sunghwan SUH ; Ji In LEE ; Kyu Yeon HUR ; Jae Hoon CHUNG ; Moon Kyu LEE ; Yong Ki MIN ; Jae Hyeon KIM ; Jong Hyun KIM ; Kwang Won KIM
Journal of Korean Medical Science 2012;27(2):177-183
The aim of this study was to assess the prevalence of diabetes and to study the effects of excess growth hormone (GH) on insulin sensitivity and beta-cell function in Korean acromegalic patients. One hundred and eighty-four acromegalic patients were analyzed to assess the prevalence of diabetes, and 52 naive acromegalic patients were enrolled in order to analyze insulin sensitivity and insulin secretion. Patients underwent a 75 g oral glucose tolerance test with measurements of GH, glucose, insulin, and C-peptide levels. The insulin sensitivity index and beta-cell function index were calculated and compared according to glucose status. Changes in the insulin sensitivity index and beta-cell function index were evaluated one to two months after surgery. Of the 184 patients, 17.4% were in the normal glucose tolerance (NGT) group, 45.1% were in the pre-diabetic group and 37.5% were in the diabetic group. The insulin sensitivity index (ISI0,120) was significantly higher and the HOMA-IR was lower in the NGT compared to the diabetic group (P = 0.001 and P = 0.037, respectively). The ISI0,120 and disposition index were significantly improved after tumor resection. Our findings suggest that both insulin sensitivity and beta-cell function are improved by tumor resection in acromegalic patients.
Acromegaly/*diagnosis/etiology/metabolism
;
Adult
;
Asian Continental Ancestry Group
;
Blood Glucose/analysis
;
C-Peptide/analysis
;
Diabetes Mellitus/epidemiology
;
Female
;
Glucose Tolerance Test
;
Human Growth Hormone/secretion
;
Humans
;
Insulin/blood/secretion
;
*Insulin Resistance
;
Insulin-Secreting Cells/cytology/*physiology
;
Male
;
Middle Aged
;
Prediabetic State/epidemiology
;
Republic of Korea
4.Change in Somatostatinergic Tone of Acromegalic Patients according to the Size of Growth Hormone-Producing Pituitary Tumors.
Sang Ouk CHIN ; Suk CHON ; You Cheol HWANG ; In Kyung JEONG ; Seungjoon OH ; Sung Woon KIM
Journal of Korean Medical Science 2013;28(12):1774-1780
The aim of this study was to investigate the relationship between somatostatinergic tone (SST) and the size of growth hormone (GH)-producing pituitary tumors. GH levels of 29 patients with newly diagnosed acromegaly were measured using a 75-gram oral glucose tolerance test (OGTT), an insulin tolerance test (ITT), and an octreotide suppression test (OST). Differences between GH levels during the ITT and the OGTT (DeltaGH(IO)), and between the OGTT and the OST at the same time point (DeltaGH(OS)) were compared according to the size of the tumor and the response pattern to the OST. DeltaGH(IO) of macroadenomas (n=22) was non-significantly higher than those of microadenomas while DeltaGH(OS) of macroadenomas were significantly higher than those of microadenomas. According to further analyses of macroadenomas based on the response pattern to the OST, GH levels during the ITT were significantly higher in non-responders. DeltaGH(OS) showed near-significant differences between responders and non-responders. In conclusion, as the size of the pituitary tumor increases, the effect of glucose on SST appears to be attenuated. Macroadenomas that are non-responders to the OST possess a portion of GH secretion exceeding the range of regulation by SST.
Acromegaly/*diagnosis/*pathology
;
Adenoma/drug therapy/*pathology
;
Adult
;
Aged
;
Antineoplastic Agents, Hormonal/therapeutic use
;
Female
;
Glucose Tolerance Test
;
Human Growth Hormone/*blood/secretion
;
Humans
;
Insulin/blood
;
Insulin-Like Growth Factor I/analysis
;
Male
;
Middle Aged
;
Octreotide/therapeutic use
;
Pituitary Neoplasms/drug therapy/*pathology